Episode Details
Back to Episodes
Daily Roundup | Wainua Fails Pivotal ATTR-CM Trial; Ionis Sinks 20%
Published 2 weeks ago
Description
AstraZeneca and Ionis's Wainua missed its Phase 3 ATTR-CM endpoint — Ionis fell ~20% while BridgeBio surged ~17%. We break down the CARDIO-TTRansform failure and what it means for Alnylam's Amvuttra and BridgeBio's Attruby, plus Roche scrapping tominersen in Huntington's, GSK exiting its Alector pact, Ipsen's Dysport dual Phase 3 migraine wins, Vera Therapeutics' IgA nephropathy approval versus Otsuka, NICE rejecting Amgen's Lumakras, and Sino Biopharm's China deals with AstraZeneca and GSK.
Visit us at thepharmacloseout.com.